Workflow
Industrial sterilization equipment and services
icon
Search documents
IBA integrates Artificial Intelligence Quality Assurance into dosimetry solutions through the acquisition of PhantomX GmbH
Globenewswire· 2025-11-03 06:00
Core Insights - IBA has announced the acquisition of PhantomX GmbH, enhancing its healthcare diagnostics and therapeutic systems with AI quality assurance capabilities [1][3] Company Overview - IBA (Ion Beam Applications S.A.) is a global leader in particle accelerator technology, specializing in proton therapy, industrial sterilization, radiopharmaceuticals, and dosimetry [5] - The company is based in Louvain-la-Neuve, Belgium, and employs approximately 2,100 people worldwide [5] - IBA is listed on the EURONEXT stock exchange and is a certified B Corporation, meeting high social and environmental performance standards [6] PhantomX GmbH - Founded in 2018 by Dr. Paul Jahnke and Dr. Felix Schwarz, PhantomX is recognized for developing realistic anthropomorphic phantoms and advanced quality assurance technologies for medical imaging [2] - The company focuses on AI validation in medical imaging and provides tools for AI-enhanced clinical solutions [2] Strategic Implications - The acquisition of PhantomX is expected to complement IBA's Clinical Workflow Solutions in Radiation Therapy and Medical Imaging, accelerating innovation through simulation and AI-driven technologies [3] - This merger aims to expand PhantomX's technology into new markets, contributing to the development of intelligent and effective medical solutions [3]
IBA – Transparency Notification - Denominator
Globenewswire· 2025-06-30 16:00
Company Overview - IBA (Ion Beam Applications S.A.) is a global leader in particle accelerator technology, specializing in proton therapy, industrial sterilization, radiopharmaceuticals, and dosimetry [5][6] - The company is headquartered in Louvain-la-Neuve, Belgium, and employs approximately 2,100 people worldwide [5] - IBA is recognized as a certified B Corporation (B Corp), meeting high standards of verified social and environmental performance [5] Shareholder Information - The total capital of IBA is EUR 42,502,318.54, with 30,282,218 securities conferring voting rights [2] - The existing voting rights amount to 40,516,629, which is the denominator for calculating the quota of voting rights that can trigger notification requirements [2] - The statutory ceiling for voting at general meetings is set at 35% of the total voting rights, equating to 14,180,820.2 votes [5] Voting Rights and Regulations - IBA has introduced loyalty voting rights, which apply to registered shares held for at least two consecutive years [3] - The calculation method for loyalty voting rights is based on the LIFO (last in, first out) principle [4] - The company must publish changes in the number of voting rights at the end of each calendar month when such changes occur [1][2]